A glutathione-sensitive drug delivery system based on carboxymethyl chitosan co-deliver Rose Bengal and oxymatrine for combined cancer treatment. Issue 5 (24th March 2023)

• Record Type: Journal Article
• Authors: Li, Juncan; Yuan, Ming; Qiu, Tong; Lu, Mengli; Zhan, Siwen; Bai, Yuting; Yang, Mengjia; Liu, Xia; Zhang, Xueqiong
• Is Part Of: Journal of biomaterials science. Volume 34:Issue 5(2023)
• Page Start: 650
• Page End: 673
• Publication Date: 2023-03-24
• Subjects: Co-delivery nanoparticles -- glutathione response -- Rose Bengal -- oxymatrine -- carboxymethyl chitosan -- oral cancer; Polymers -- Biocompatibility -- Periodicals; Biomedical materials -- Periodicals; 572.33
• DOI: 10.1080/09205063.2022.2139977
• Languages: English
• ISSNs: 0920-5063

Abstract

Abstract: At present, monotherapy of tumor has not met the clinical needs, due to high doses, poor efficacy, and the emergence of drug resistance. Combination therapy can effectively solve these problems, which is a better option for tumor suppression. Based on this, we developed a novel glutathione-sensitive drug delivery nanoparticle system (OMT/CMCS-CYS-RB NPs) for oral cancer treatment. Briefly, carboxymethyl chitosan (CMCS) was used as a carrier to simultaneously load Rose Bengal (RB) and oxymatrine (OMT). The OMT/CMCS-CYS-RB NPs prepared by ion crosslinking were spheres with a stable structure. In addition, the nanoparticles can be excited in vitro to generate a large amount of singlet oxygen, which has a good photodynamic effect. In vitro anti-tumor activity study showed that the nanoparticles after the laser enhanced therapeutic efficacy on tumor cells compared with the free drug and exhibited well security. Furthermore, OMT/CMCS-CYS-RB NPs could inhibit the PI3K/AKT signaling pathway in oxidative stress, and realize tumor apoptosis through mitochondria-related pathways. In conclusion, this combination delivery system for delivering RB and OMT is a safe and effective strategy, which may provide a new avenue for the tumor treatment.